>> you have to think of the fact we only have one planet, so we should treat the planet as an unreviewableesource, and obviously the more people we have on it the more strange we have,. >> our planet is getting hot, flat, crowded, and what that means is basically, on the one hand it is getting hot, global warming. we know that is happening. but will also happen faster as it is getting flat, that means more and more people from american point of you can see how we live. livespired to live what we that means more people living in, american size homes, driving cars, american business. if we do not find a more sustainable business to satisfy those aspirations of all of these people who want and now can have our lifestyle, that is a wonderful thing, but if we do it in a more sustainable way we are going to burn up, choke up this planet. and that itself will drive a myriad number of problems. ♪ >> the greatest threat facing humanity today have to be climate change, followed by the possibility of nuclear war, because those are the only two things on the horizon that could destroy all of humanity.

the field, gus, was he was contacted and then re-established and that was a catch this would be unreviewable. >> referee: the ruling ruling on the field is confirmed. illegal touching. it will be second down. >> joel: the rule book is lengthy and nuanced but this is one of those areas that last year came under fire. remember the michigan state-notre dame game. the re-establishing inbounds, was he contacted to go out? was it forcible, so on and so officiating crew doing a nice job at the end of the game. >> gus: second down and ten. here is rudolph. winds up. uncomplete. that is short. >> gus: intended for chris lacy. third and ten with a 1:03 to go. >> joel: this sets baylor up well. they understand they can win several types of we have seen them get in the shootout. now they are in a slugfest for them. in particular on the defensive side. oklahoma state came out to rush the ball 37 times. the defensive front for baylor did a great job. middle. tackle hard by aiavion edwards. the clock continues to run. oklahoma state can't stop it. >> joel: should have drawn a foul. absolutely should have d

queue prior to 2012 prior to the passage, the number of products in the queue in 2012 that are unreviewed, less than 100. we have reviewed 90% of those to provide feedback to the sponsors. >> how many epinephrine products? >> can't answer that question. >> you know that number? >> i do not know that number. >> why are we having a hearing about this? >> you know that number. here is the thing. they may tell you had the fda we never talk about this, i don't care. congress doesn't care. i want to know how many epinephrine oriented products there are right now? >> i wish i could answer that. i can get back whatever information i can to you as quickly as i can. >> we you give back the answer i asked be change i will provide whatever information i can. >> are you going to answer the question i asked? >> is. >> will the gentleman agree, give them five minutes to get answers you. i yelled back. >> how hard is it to get the answer? who knows that answer? >> i am not allowed -- simply a legal answer. i'm not allowed to disclose confidential information in this setting. my understanding -- >> let me

dodd frank living will created the fdic and the fed unbridled and unreviewable discretion to restructure private businesses under a process that relies entirely on the personal discretion of washington regulators. indeed it stands at the center of the too big to fail. it occupies the board rooms of the largest financial thstitutions in our nation andnd this decides if they can deploy their capital sending a signal that washington will bail them out if they get into trouble. despite claims by this fed that it taylor's institutions, we know small banks are suffering disproportionately under washington's thumb. as we lose on average one.mm day, they lose lose options to help them achieve financial independence and they lose the opportunity to grow job. given elevated capital buffers they need to be for less concerned about the portfoliose since any losses would be absorbed by shareholders, not taxpayers. this would enable the dodd frank act. current chair has said u.s. banks engaged in core banking ad activity. former chair has also expressed support of use of higher capital levels in place

>> the number of products that were in the queue in 2012 that remain unreviewed, less than 100. we have reviewed well over 90% of those products and provided feedback to the sponsors. >> how many epinephrine-oriented products are in the pipeline right now? >> i can't answer that question i'm afraid, congressman. >> no. wait. do you know that number? >> i do not know that number right now, sir. >> we're having a hearing about this. do you know that number? >> what i can -- >> here is the thing, they may tell you at the fda, hey, we don't ever talk about this. i don't care. okay? congress doesn't care about that. i want to know how many epinephrine-oriented products are in the queue right now. >> i wish that i could answer that question. >> when can you give me that answer? >> i can get back whatever information i can to you as quickly as i can. >> are you going to get back the answer to the question i asked? >> i will be able to provide whatever information i can. >> are you going to answer the question that i asked? >> mr. chairman. >> yes. >> mr. lynch. >> would the gentlemen -

>> the number of products that were in the queue in 2012 that remain unreviewed, less than 100.e have reviewed well over 90% of those products and provided feedback to the sponsors. >> how many epinephrine-oriented products are in the pipeline right now? >> i can't answer that question i'm afraid, congressman. >> no. wait. do you know that number? >> i do not know that number right now, sir. >> we're having a hearing about this. do you know that number? >> what i can -- >> here is the thing, they may tell you at the fda, hey, we don't ever talk about this. i don't care. okay? congress doesn't care about that. i want to know how many epinephrine-oriented products are in the queue right now. >> i wish that i could answer that question. >> when can you give me that answer? >> i can get back whatever information i can to you as quickly as i can. >> are you going to get back the answer to the question i asked? >> i will be able to provide whatever information i can. >> are you going to answer the question that i asked? >> mr. chairman. >> yes. >> mr. lynch. >> would the gentlemen --

>> the number of products that were in the queue in 2012 that remain unreviewed, less than 100. we have reviewed well over 90% of those products and provided feedback to the sponsors . >> how many epinephrine-oriented products are in the pipeline right now? >> i can't answer that question i'm afraid, congressman. >> no. wait. do you know that number? >> i do not know that number right now, sir. >> we're having a hearing about this. do you know that number? >> what i can -- >> here is the thing, they may tell you at the fda, hey, we don't ever talk about this. i don't care. okay? congress doesn't care about that. i want to know how many epinephrine-oriented products are in the queue right now. >> i wish that i could answer that question. >> when can you give me that answer? >> i can get back whatever information i can to you as quickly as i can. >> are you going to get back the answer to the question i asked? >> i will be able to provide whatever information i can. >> are you going to answer the question that i asked? >> mr. chairman. >> yes. >> mr. lynch. >> would the gentlemen